Pete Lollar

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi Molecular characterization of the immune response to factor VIII
    Pete Lollar
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Vox Sang 83:403-8. 2002
  2. ncbi The factor VIII assay problem: neither rhyme nor reason
    P Lollar
    Emory University, Atlanta, GA, USA
    J Thromb Haemost 1:2275-9. 2003
  3. ncbi Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
    P Lollar
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 2:1082-95. 2004
  4. ncbi Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor
    P Lollar
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 3:1385-91. 2005
  5. ncbi Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules
    P Lollar
    Department of Medicine, Emory University, Atlanta, GA 30322, USA
    Haematologica 85:26-8; discussion 28-30. 2000
  6. ncbi Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis
    I M Lubin
    Department of Medicine, Emory University, Atlanta, Georgia 30322, USA
    J Biol Chem 272:30191-5. 1997
  7. ncbi Hemophilia and immunology at the crossroads
    P Lollar
    Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Atlanta, GA, USA
    J Thromb Haemost 4:2170-1. 2006
  8. ncbi A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA
    Blood 120:2512-20. 2012
  9. ncbi Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope
    Ernest T Parker
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 104:704-10. 2004
  10. ncbi Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA
    Blood 110:4234-42. 2007

Research Grants

  1. STRUCTURE AND FUNCTION OF THE FACTOR VIII-VWF COMPLEX
    JOHN LOLLAR; Fiscal Year: 2005
  2. The Immune Response to Factor VIII
    JOHN LOLLAR; Fiscal Year: 2007
  3. Structure and Function of the Factor VIII - von Willebrand Factor Complex
    JOHN S LOLLAR; Fiscal Year: 2010
  4. STRUCTURE/FUNCTION OF THE FACTOR VIII VWF COMPLEX
    JOHN LOLLAR; Fiscal Year: 2001
  5. STRUCTURE AND FUNCTION OF THE FACTOR VIII-VWF COMPLEX
    JOHN LOLLAR; Fiscal Year: 1993
  6. STRUCTURE/FUNCTION OF F-VIII-WILLEBRAND FACTOR COMPLEX
    JOHN LOLLAR; Fiscal Year: 1992
  7. The Immune Response to Factor VIII
    JOHN S LOLLAR; Fiscal Year: 2010

Collaborators

  • Christopher B Doering
  • D Scandella
  • Boro Dropulic
  • Yi Lin
  • Christine L Kempton
  • JOHN LOLLAR
  • Ernest T Parker
  • JOHN S LOLLAR
  • Shannon L Meeks
  • John F Healey
  • Rachel T Barrow
  • R T Barrow
  • J F Healey
  • E T Parker
  • Bagirath Gangadharan
  • Ryan J Summers
  • H Trent Spencer
  • I M Lubin
  • F Lian
  • H Wu
  • Bhavya S Doshi
  • Courtney L Cox
  • Gabriela Denning
  • Lajos Baranyi
  • Harrison C Brown
  • Richard E Gautney
  • Andre J Roy
  • Travis J Langley
  • William R Church
  • T J Langley
  • W R Church
  • Heather N Craddock
  • H N Craddock
  • E Parker
  • L He
  • D K Okita
  • D M Tollefsen
  • M Reding
  • J Qian
  • B M Conti-Fine
  • L W Hoyer
  • N S Colwell
  • M S Runge

Detail Information

Publications32

  1. ncbi Molecular characterization of the immune response to factor VIII
    Pete Lollar
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Vox Sang 83:403-8. 2002
    ..A murine hemophilia A model has been developed to study the immunogenicity of factor VIII. This model may lead to improved approaches to prevent development of inhibitory antibodies and to reverse the immune response if it develops...
  2. ncbi The factor VIII assay problem: neither rhyme nor reason
    P Lollar
    Emory University, Atlanta, GA, USA
    J Thromb Haemost 1:2275-9. 2003
  3. ncbi Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
    P Lollar
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 2:1082-95. 2004
  4. ncbi Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor
    P Lollar
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 3:1385-91. 2005
  5. ncbi Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules
    P Lollar
    Department of Medicine, Emory University, Atlanta, GA 30322, USA
    Haematologica 85:26-8; discussion 28-30. 2000
    ..The manipulation of inhibitor epitopes using recombinant DNA technology may lead to improved forms of FVIII that have lower antigenicity and/or lower immunogenicity...
  6. ncbi Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis
    I M Lubin
    Department of Medicine, Emory University, Atlanta, Georgia 30322, USA
    J Biol Chem 272:30191-5. 1997
    ..The side chains recognized by human A2 inhibitors appear to be similar, despite the differing immune settings that give rise to fVIII alloantibodies and autoantibodies...
  7. ncbi Hemophilia and immunology at the crossroads
    P Lollar
    Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Atlanta, GA, USA
    J Thromb Haemost 4:2170-1. 2006
  8. ncbi A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Center, Department of Pediatrics, Emory University, Atlanta, GA 30322, USA
    Blood 120:2512-20. 2012
    ....
  9. ncbi Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope
    Ernest T Parker
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 104:704-10. 2004
    ....
  10. ncbi Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation
    Shannon L Meeks
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Department of Pediatrics, Emory University, Atlanta, GA, USA
    Blood 110:4234-42. 2007
    ..These results reveal the structural and functional complexity of the anti-C2 domain antibody response and indicate that interference with fVIII activation is a major attribute of the inhibitor landscape...
  11. ncbi Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein
    Ryan J Summers
    Emory University School of Medicine, Atlanta, GA, USA
    Blood 117:3190-8. 2011
    ....
  12. ncbi Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion
    Christopher B Doering
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    J Biol Chem 279:6546-52. 2004
    ..Metabolic radiolabeling experiments demonstrated that high level expression was attributable to enhanced secretory efficiency...
  13. ncbi Expression and characterization of recombinant murine factor VIII
    Christopher Doering
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    Thromb Haemost 88:450-8. 2002
    ..This may provide an important model for the study of immune tolerance to fVIII...
  14. ncbi Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors
    Shannon L Meeks
    Department of Pediatrics, Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA30322, USA
    Blood 112:1151-3. 2008
    ..Most of the anti-C2 inhibitor plasmas inhibited the binding of both classical and nonclassical antibodies. These results suggest that nonclassical anti-C2 antibodies contribute significantly to the pathogenicity of fVIII inhibitors...
  15. ncbi A1 subunit-mediated regulation of thrombin-activated factor VIII A2 subunit dissociation
    Ernest T Parker
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, Georgia 30322, USA
    J Biol Chem 281:13922-30. 2006
    ..We propose that cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant...
  16. ncbi The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice
    John F Healey
    Aflac Cancer Center and Blood Disorders Service, Department of Pediatrics, Children s Healthcare of Atlanta and Emory University, Atlanta, Georgia, USA
    Thromb Haemost 102:35-41. 2009
    ..The differential immune response to human and porcine FVIII suggests that it may be possible to reduce the immunogenicity of FVIII by mutagenesis of the A2, A3 and C1 domains...
  17. ncbi Contribution of A1 subunit residue Q316 in thrombin-activated factor VIII to A2 subunit dissociation
    Ernest T Parker
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta, and the Department of Pediatrics, Emory University, Atlanta, Georgia 30322, USA
    Biochemistry 46:9737-42. 2007
    ..These results indicate that the FG helix of the COOH-terminal A1 cupredoxin-like subdomain of fVIII may be under selective pressure by the requirements of hemostatic balance...
  18. ncbi Decreased factor VIII levels during acetaminophen-induced murine fulminant hepatic failure
    Christopher B Doering
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 102:1743-4. 2003
    ..These results imply that there are fundamental differences in the regulation of plasma fVIII levels between humans and mice...
  19. ncbi High level expression of recombinant porcine coagulation factor VIII
    Christopher B Doering
    Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA
    J Biol Chem 277:38345-9. 2002
    ..The identification of sequence(s) in porcine factor VIII responsible for high level expression may lead to a better understanding of the mechanisms that limit factor VIII expression...
  20. ncbi A quantitative measure of the efficacy of factor VIII in hemophilia A mice
    Ernest T Parker
    1639 Pierce Drive, Room 1003 Woodruff Memorial Building, Emory University, Atlanta, GA 30322, USA
    Thromb Haemost 89:480-5. 2003
    ..4-78.5 units/kg). This method should be useful in the evaluation and comparison of novel factor VIII products delivered either parenterally or in a gene therapy setting...
  21. ncbi Use of blood outgrowth endothelial cells for gene therapy for hemophilia A
    Yi Lin
    Department of Medicine, University of Minnesota Medical School, Minneapolis 55455, USA
    Blood 99:457-62. 2002
    ..Thus, the use of engineered autologous BOECs, which here resulted in sustained and therapeutic levels of FVIII, may comprise an effective therapeutic strategy for use in gene therapy for hemophilia A...
  22. ncbi Factor VIII expression in azoxymethane-induced murine fulminant hepatic failure
    Christopher B Doering
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 100:143-7. 2002
    ..These results indicate that the contribution of the liver to factor VIII biosynthesis is not replaced or significantly supplemented by other tissues in this model of FHF...
  23. ncbi Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII
    H Trent Spencer
    Department of Pediatrics, Emory University School of Medicine and Children s Healthcare of Atlanta, Atlanta, GA, USA
    Mol Ther 19:302-9. 2011
    ..5 mg/l of recombinant fVIII at the rate of 9 pg/cell/day, which is the highest level of recombinant fVIII production reported to date, thereby validating the utility of both technologies...
  24. ncbi Elimination of a major inhibitor epitope in factor VIII
    I M Lubin
    Department of Medicine, Emory University, Atlanta, Georgia 30322
    J Biol Chem 269:8639-41. 1994
    ..In contrast, the hybrid was neutralized by an anti-C2 antibody. These findings provide a basis for fine epitope mapping and for therapy of the inhibitor patient...
  25. ncbi Degradation of coagulation proteins by an enzyme from Malayan pit viper (Akistrodon rhodostoma) venom
    P Lollar
    Department of Medicine, University of Vermont, Burlington 05405
    Biochemistry 26:7627-36. 1987
    ..These findings may have relevance to studies of hemostatic derangements following envenomation by this snake. Additionally, several novel coagulation factor derivatives have been generated for structure-function studies...
  26. ncbi The humoral response to human factor VIII in hemophilia A mice
    J F Healey
    Aflac Cancer Center and Blood Disorders Service, Department of Pediatrics, Children s Healthcare of Atlanta and Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 5:512-9. 2007
    ..Inhibitory antibodies (Abs) to factor VIII (FVIII inhibitors) constitute the most significant complication in the management of hemophilia A. The analysis of FVIII inhibitors is confounded by polyclonality and the size of FVIII...
  27. ncbi Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII
    R T Barrow
    Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Atlanta, GA 30322, USA
    J Thromb Haemost 4:2223-9. 2006
    ....
  28. ncbi Mechanism of the immune response to human factor VIII in murine hemophilia A
    H Wu
    Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis-St Paul, 55108, USA
    Thromb Haemost 85:125-33. 2001
    ....
  29. ncbi Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin
    F Lian
    Division of Hematology, Department of Internal Medicine, Washington University, St. Louis, Missouri 63110, USA
    Biochemistry 40:8508-13. 2001
    ....
  30. ncbi Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII
    E T Parker
    Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    J Thromb Haemost 2:605-11. 2004
    ..02 and P = 0.004, respectively). The results using this model suggest that OBI-1 may be less immunogenic and safer than Hyate:C in FVIII inhibitor patients...
  31. ncbi Association of the factor VIII light chain with von Willebrand factor
    P Lollar
    Department of Medicine and Biochemistry, University of Vermont, Burlington 05405
    J Biol Chem 263:10451-5. 1988
    ..These data are consistent with the hypothesis that a critical step in blood coagulation is the release of all regions of fVIII from vWF following a single proteolytic cleavage of fVIIILC...
  32. ncbi The cDNA and derived amino acid sequence of porcine factor VIII
    J F Healey
    Department of Medicine, Emory University, Atlanta GA 30322, USA
    Blood 88:4209-14. 1996
    ..A patients through the development of recombinant porcine fVIII or hybrid human/porcine fVIII derivatives...

Research Grants23

  1. STRUCTURE AND FUNCTION OF THE FACTOR VIII-VWF COMPLEX
    JOHN LOLLAR; Fiscal Year: 2005
    ..Additionally, we will identify the mechanism of differential expression of porcine versus human fVIII by using cell-free translation and co-translational processing systems. ..
  2. The Immune Response to Factor VIII
    JOHN LOLLAR; Fiscal Year: 2007
    ..As an outcome of this project, new therapeutic and diagnostic approaches in the management of Hemophilia A will be produced. ..
  3. Structure and Function of the Factor VIII - von Willebrand Factor Complex
    JOHN S LOLLAR; Fiscal Year: 2010
    ..abstract_text> ..
  4. STRUCTURE/FUNCTION OF THE FACTOR VIII VWF COMPLEX
    JOHN LOLLAR; Fiscal Year: 2001
    ..The characterization of fVIII gene expression in vivo may lead to better approaches toward somatic cell gene therapy of hemophilia A. ..
  5. STRUCTURE AND FUNCTION OF THE FACTOR VIII-VWF COMPLEX
    JOHN LOLLAR; Fiscal Year: 1993
    ..Taken together, these studies will provide the basis for a quantitative model of the fVIII-vWf complex...
  6. STRUCTURE/FUNCTION OF F-VIII-WILLEBRAND FACTOR COMPLEX
    JOHN LOLLAR; Fiscal Year: 1992
    ..Finally, stopped-flow light scattering studies have shown the binding of fVIII and WF is accompanied by a large increase in light scattering so that the kinetics of the interaction can be measured...
  7. The Immune Response to Factor VIII
    JOHN S LOLLAR; Fiscal Year: 2010
    ..In Aim 2, murine antibodies of defined specificity produced in Aim 1 will be used to identify novel factor VIII antibody epitopes recognized by human hemophilia A patients. ..